Catalyst Biosciences, Inc. – NASDAQ:CBIO

Financial Health
0
1
2
3
4
5
6
7
8
9

Catalyst Biosciences stock price monthly change

+5.95%
month

Catalyst Biosciences stock price quarterly change

+75.30%
quarter

Catalyst Biosciences stock price yearly change

-12.02%
year

Catalyst Biosciences key metrics

Market Cap
19.41M
Enterprise value
471.74K
P/E
1.25
EV/Sales
-0.59
EV/EBITDA
N/A
Price/Sales
-10.79
Price/Book
1.16
PEG ratio
0.05
EPS
-1.37
Revenue
N/A
EBITDA
-40.79M
Income
-44.24M
Revenue Q/Q
N/A
Revenue Y/Y
-124.55%
Profit margin
-860.96%
Oper. margin
-789.42%
Gross margin
200.5%
EBIT margin
-789.42%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Catalyst Biosciences stock price history

Catalyst Biosciences stock forecast

Catalyst Biosciences financial statements

Catalyst Biosciences, Inc. (NASDAQ:CBIO): Profit margin
Dec 2022 -794K -40.45M 5094.96%
Mar 2023 0 260K
Jun 2023 0 -2.47M
Sep 2023 0 -1.57M
Catalyst Biosciences, Inc. (NASDAQ:CBIO): Analyst Estimates
2025 3.17M -638K -20.09%
  • Analysts Price target

  • Financials & Ratios estimates

735.68%
Yield TTM
Catalyst Biosciences, Inc. (NASDAQ:CBIO): Payout ratio
Payout ratio 772.31%
Catalyst Biosciences, Inc. (NASDAQ:CBIO): Dividend Yield
2018
2019
2020
2021
2022 270.61%
Catalyst Biosciences, Inc. (NASDAQ:CBIO): Debt to assets
Mar 2023 18750000 44.70M 238.42%
Jun 2023 12394000 40.70M 328.45%
Sep 2023 9964000 6.44M 64.7%
Dec 2023 62394370 0 0%
Catalyst Biosciences, Inc. (NASDAQ:CBIO): Cash Flow
Dec 2022 -1.47M 51K 16K
Mar 2023 -6.21M 411K -7.76M
Jun 2023 -2.47M 4.79M -3.5M
Sep 2023 -3.21M 1M -1.47M

Catalyst Biosciences alternative data

Catalyst Biosciences, Inc. (NASDAQ:CBIO): Employee count
Sep 2023 7
Oct 2023 7
Nov 2023 7
Dec 2023 7
Jan 2024 7
Feb 2024 7
Mar 2024 7
Apr 2024 7
May 2024 7
Jun 2024 7
Jul 2024 7

Catalyst Biosciences other data

6.74% -9.13%
of CBIO is owned by hedge funds
2.12M -2.86M
shares is hold by hedge funds

Catalyst Biosciences, Inc. (NASDAQ:CBIO): Insider trades (number of shares)
Period Buy Sel
Oct 2023 8111111 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
GNI GROUP LTD. 10 percent owner
Series X Convertible Preferred Stock Warrant (Right to Buy) 8,110,300 N/A N/A
Purchase
GNI GROUP LTD. 10 percent owner
Series X Convertible Preferred Stock 811 N/A N/A
Purchase
BLOUSE GRANT E. officer: Chief Scientific Officer
Common Stock 3,250 $0.47 $1,528
Purchase
MILLER SELINE E. officer: SVP Finance; Interim C..
Common Stock 3,250 $0.47 $1,528
Purchase
USMAN NASSIM officer: Presiden.. Common Stock 3,250 $0.47 $1,528
Purchase
USMAN NASSIM director, officer.. Common Stock 3,250 $0.46 $1,495
Purchase
MILLER SELINE E. officer: SVP Finance; Interim C..
Common Stock 3,250 $0.46 $1,495
Purchase
BLOUSE GRANT E. officer: Chief Scientific Officer
Common Stock 3,250 $0.46 $1,495
Purchase
BLOUSE GRANT E.
Common Stock 1,163 $3.62 $4,210
Purchase
LEVY HOWARD officer: Chief Medical Officer
Common Stock 639 $3.62 $2,313
Patent
Grant
Filling date: 19 Feb 2021 Issue date: 8 Mar 2022
Grant
Filling date: 2 Nov 2018 Issue date: 21 Dec 2021
Application
Filling date: 9 Jul 2021 Issue date: 18 Nov 2021
Application
Filling date: 28 Jan 2021 Issue date: 5 Aug 2021
Application
Filling date: 16 Mar 2021 Issue date: 29 Jul 2021
Application
Filling date: 3 Jan 2020 Issue date: 22 Jul 2021
Application
Filling date: 19 Feb 2021 Issue date: 24 Jun 2021
Grant
Filling date: 29 Mar 2016 Issue date: 20 Apr 2021
Grant
Filling date: 2 Jun 2020 Issue date: 23 Mar 2021
Application
Filling date: 15 Aug 2020 Issue date: 11 Mar 2021
Insider Compensation
Dr. Nassim Usman Ph.D. (1960) Pres, Chief Executive Officer & Director $769,180
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. (1954) Consultant
$577,040
Monday, 30 October 2023
globenewswire.com
Friday, 21 July 2023
businesswire.com
Tuesday, 7 March 2023
prnewswire.com
Tuesday, 28 February 2023
InvestorPlace
Monday, 15 August 2022
Seeking Alpha
Tuesday, 28 June 2022
Zacks Investment Research
Friday, 17 June 2022
PennyStocks
Wednesday, 25 May 2022
PennyStocks
Tuesday, 24 May 2022
PennyStocks
Monday, 23 May 2022
InvestorPlace
Benzinga
Benzinga
PennyStocks
Wednesday, 12 January 2022
Zacks Investment Research
Wednesday, 13 October 2021
GlobeNewsWire
Tuesday, 28 September 2021
GlobeNewsWire
Friday, 24 September 2021
GlobeNewsWire
  • When is Catalyst Biosciences's next earnings date?

    Unfortunately, Catalyst Biosciences's (CBIO) next earnings date is currently unknown.

  • Does Catalyst Biosciences pay dividends?

    Yes, Catalyst Biosciences pays dividends and its trailing 12-month yield is 735.68% with 772% payout ratio.It means that the company is paying a dividend greater than earnings. The last Catalyst Biosciences stock dividend of $0.57 was paid on 19 Aug 2015.

  • How much money does Catalyst Biosciences make?

    Catalyst Biosciences has a market capitalization of 19.41M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 89.18% to 794K US dollars.

  • What is Catalyst Biosciences's stock symbol?

    Catalyst Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "CBIO".

  • What is Catalyst Biosciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Catalyst Biosciences?

    Shares of Catalyst Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Catalyst Biosciences's key executives?

    Catalyst Biosciences's management team includes the following people:

    • Dr. Nassim Usman Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $769,180)
    • Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. Consultant(age: 71, pay: $577,040)
  • How many employees does Catalyst Biosciences have?

    As Jul 2024, Catalyst Biosciences employs 7 workers.

  • When Catalyst Biosciences went public?

    Catalyst Biosciences, Inc. is publicly traded company for more then 19 years since IPO on 12 Apr 2006.

  • What is Catalyst Biosciences's official website?

    The official website for Catalyst Biosciences is catalystbiosciences.com.

  • Where are Catalyst Biosciences's headquarters?

    Catalyst Biosciences is headquartered at 611 Gateway Boulevard, South San Francisco, CA.

  • How can i contact Catalyst Biosciences?

    Catalyst Biosciences's mailing address is 611 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 08710761.

Catalyst Biosciences company profile:

Catalyst Biosciences, Inc.

catalystbiosciences.com
Exchange:

NASDAQ

Full time employees:

7

Industry:

Biotechnology

Sector:

Healthcare

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

611 Gateway Boulevard
South San Francisco, CA 94080

CIK: 0001124105
ISIN: US4037831033
CUSIP: 14888D208